BioMarin Pharmaceutical, Inc. (BMRN)
57.23
+0.53
(+0.93%)
USD |
NASDAQ |
Nov 13, 16:00
57.27
+0.04
(+0.07%)
After-Hours: 06:31
BioMarin Pharmaceutical EPS Diluted (Quarterly) : -0.6345 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.6345 |
| June 30, 2026 | 0.2302 |
| March 31, 2026 | 0.5431 |
| December 31, 2025 | -0.2423 |
| September 30, 2025 | -0.1601 |
| June 30, 2025 | 1.230 |
| March 31, 2025 | 0.9544 |
| December 31, 2024 | 0.6449 |
| September 30, 2024 | 0.5474 |
| June 30, 2024 | 0.5483 |
| March 31, 2024 | 0.4588 |
| December 31, 2023 | 0.1062 |
| September 30, 2023 | 0.2112 |
| June 30, 2023 | 0.2922 |
| March 31, 2023 | 0.2616 |
| December 31, 2022 | -0.0013 |
| September 30, 2022 | -0.0358 |
| June 30, 2022 | 0.1476 |
| March 31, 2022 | 0.6198 |
| December 31, 2021 | -0.3154 |
| September 30, 2021 | -0.1992 |
| June 30, 2021 | 0.0698 |
| March 31, 2021 | 0.0942 |
| December 31, 2020 | 0.0655 |
| September 30, 2020 | 4.006 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.1615 |
| March 31, 2020 | 0.4398 |
| December 31, 2019 | 0.0824 |
| September 30, 2019 | 0.301 |
| June 30, 2019 | -0.2091 |
| March 31, 2019 | -0.3168 |
| December 31, 2018 | -0.0205 |
| September 30, 2018 | -0.07 |
| June 30, 2018 | -0.09 |
| March 31, 2018 | -0.26 |
| December 31, 2017 | -0.29 |
| September 30, 2017 | -0.07 |
| June 30, 2017 | -0.21 |
| March 31, 2017 | -0.09 |
| December 31, 2016 | -0.53 |
| September 30, 2016 | -0.22 |
| June 30, 2016 | -2.58 |
| March 31, 2016 | -0.51 |
| December 31, 2015 | 0.39 |
| September 30, 2015 | -0.60 |
| June 30, 2015 | -0.51 |
| March 31, 2015 | -0.43 |
| December 31, 2014 | -0.47 |
| September 30, 2014 | 0.05 |
| June 30, 2014 | -0.23 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Exelixis, Inc. | 0.8528 |
| Ascendis Pharma A/S | 1.239 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Arrowhead Pharmaceuticals, Inc. | -3.029 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -122.83M |
| Revenue (Quarterly) | 1.025B |
| Total Expenses (Quarterly) | 1.147B |
| Enterprise Value | 14.55B |
| Gross Profit Margin (Quarterly) | 70.24% |
| Profit Margin (Quarterly) | -11.99% |
| Earnings Yield | -0.18% |
| Operating Earnings Yield | 6.37% |
| Normalized Earnings Yield | 3.334 |